About Contact Us Careers

Intestinal Pseudo-obstruction Treatment Market Size and Forecast, by Type (Acute, Chronic); Treatment (Medication, Surgery, Diet, Decompression); Diagnosis (Physical Exam, Biopsy, Blood Test, Gastric Emptying Tests, Imaging Tests, Manometry); Symptoms (Abdominal Pain, Bloating, Diarrhea, Vomiting, Nausea, Constipation); Dosage (Tablet, Injection); Drug Class (Antibiotic, Antidepressants, Antidiarrheal) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 5760
  • Published Date: Sep 16, 2025
  • Report Format: PDF, PPT

Intestinal Pseudo-obstruction Treatment Market Outlook:

Intestinal Pseudo-obstruction Treatment Market size was over USD 24.77 billion in 2025 and is poised to exceed USD 40.73 billion by 2035, witnessing over 5.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of intestinal pseudo-obstruction treatment is estimated at USD 25.91 billion.

Intestinal Pseudo-obstruction Treatment Market
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The increased frequency of gastrointestinal disease will propel the primary reason behind the growth of the intestinal pseudo-obstruction treatment market. As the macroeconomic prospect degenerates for the automotive industry, a modest return to expansion is anticipated for the latest clients and commercial vehicle sales in the next two years. It is projected that international vehicle sales will expand by 5.1% in 2023 and 3.6% in 2024. Moreover, automakers can project sales to come back to the 90 million+ high water mark in 2025.

Another reason that will propel the intestinal pseudo-obstruction treatment market by the end of 2036 is the cost-effective diagnosis and treatment worldwide. Patient existence was 89% at 1 year and 69% at 5 years with corresponding graft existence of 87% and 56%. Retransplantation was victorious in 86%. The primary treatment is wholesome support to stop malnutrition and antibiotics to cure bacterial infections. ailments that may coexist and deteriorate symptoms of pseudo-obstruction--like gastroparesis (postponed stomach emptying), gastroesophageal reflux, or bacterial gigantism—require to be recognized and cured. The challenges of curing chronic pseudo-obstruction are repeatedly many-sided and comprise the patient and family along with the physician. The physician may recommend a multidisciplinary technique for therapy. A maintenance team might comprise the child's pediatric gastroenterologist, a pediatric pain maintenance specialist, a behavioral expert, and others. In acute cases, surgery to eliminate part of the intestines might be important. In a subset of patients, when pseudo-obstruction is restricted to an isolated segment of the bowel, surgical bypass may be acknowledged. In the most severe cases, when patients getting total parenteral nutrition undergo life-threatening problems like severe infection or liver failure, small bowel relocation may be acknowledged. This technique is challenging and has a lot of related risks. It should only be acknowledged when all other therapy choices have been worn out.

Key Intestinal Pseudo-obstruction Treatment Market Insights Summary:

  • Regional Highlights:

    • North America intestinal pseudo-obstruction treatment market is expected to capture 45% share by 2035, driven by increasing advancement in the tools of diagnosis in this region.
    • Europe market will exhibit huge growth during the forecast timeline, driven by chronic digestive disease prevalence in the region.

  • Segment Insights:

    • The antibiotic segment in the intestinal pseudo-obstruction treatment market is expected to achieve a 68% share by 2035, driven by the extensive use of antibiotics to treat intestinal pseudo-obstruction worldwide.
    • The blood test (diagnosis) segment in the intestinal pseudo-obstruction treatment market is expected to secure a 38% share by 2035, driven by increased blood testing for detection of intestinal pseudo-obstruction.

  • Key Growth Trends:

    • Impact of the Sedentary Lifestyle
    • Advancements in Diagnostic Equipment

  • Major Challenges:

    • High Cost of Treatment of Intestinal Pseudo-obstruction
    • Side Effects Related to the Medications

  • Key Players: GlaxoSmithKline Plc., Abbott Laboratories, Pfizer Inc., Johnson & Johnson, Callisto Pharmaceuticals Inc., Biogen Inc., Novartis A.G., Canila Healthcare Ltd, AbbVie Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited., Daiichi Sankyo Co Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co Ltd.

Global Intestinal Pseudo-obstruction Treatment Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 24.77 billion
    • 2026 Market Size: USD 25.91 billion
    • Projected Market Size: USD 40.73 billion by 2035
    • Growth Forecasts: 5.1% CAGR (2026-2035)

  • Key Regional Dynamics:

    • Largest Region: North America (45% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, Germany, Japan, United Kingdom, China
    • Emerging Countries: China, India, Japan, South Korea, Brazil

    • Last updated on : 16 September, 2025

Growth Drivers

  • Impact of the Sedentary Lifestyle   - Sedentary behavior signifies less movement, so fewer calories are scorched. It’s suggested that adults and teens perform at least 2.5 hours of physical activity weekly to limit the opportunity for heart disease. However current studies demonstrate that only one in five people have the exercise they should – this can outcome in unplanned weight gain and possibly obesity. Of the many positive transformations that have happened in their production during the 21st century, one of the adverse prospects has been the kind of appearing and rising trend of a sedentary lifestyle. Related to their grandparents or parents, there is a substantial reduction in physical activity and a rise in health complexities. The indications of a sedentary lifestyle can be both physical and mental, and sometimes they’re so small that it may not even acknowledge they’re emerging. It’s significant to comprehend and recognize the indications so they can make changes to modify your health and quality of life.

  • Advancements in Diagnostic Equipment - A massively low incidence, non-particular clinical symptoms, powerful heterogeneity, and no definitive cause in some patients make CIPO very difficult to diagnose correctly. Imaging and gastrointestinal manometry are usually utilized. Most patients have advanced worsening of their symptoms and require arbitration, and nutritional assessment and treatment are very important to determine the prognosis. With modifications in surgical processes, small bowel transplantation is a possible therapy choice for patients with advanced CIPO; but, the permanent prognosis for CIPO patients stays unsatisfactory. Usually, the disease is rare and tough to diagnose, which leads to clinicians’ shortage of comprehension of the disease and outcomes in a high rate of misdiagnosis. This review explains the features of CIPO and the new developments in diagnosis and therapy, in detail. The objective of their review is to modify clinicians' comprehension of CIPO so that the disease is recognized promptly and precisely, and cured as early as feasible to modify patients’ quality of life.

  • Increasing Emphasis on Patient-Centric Care - Patients are living longer with chronic situations because of these progresses, and their role in health care is transforming from that of an inactive recipient of medical care to an active participant in clinical decision-making. These reasons are now putting the burden on the intricate, expensive, and frequently fragmented U.S. healthcare system to modify quality, as deliberated by patient experience.

Challenges

  • High Cost of Treatment of Intestinal Pseudo-obstruction - Acute colonic pseudo-obstruction is the clinical syndrome of sharp large bowel dilatation without mechanical impediment that is a significant cause of unwholesomeness and mortality. Intense colonic pseudo-obstruction takes place in hospitalized or institutionalized patients with severe fundamental medical and surgical situations. The pathogenesis of sharp colonic pseudo-obstruction is not realized but possibly results from inequality in the autonomic control of colonic motor function. Metabolic or pharmacological reasons, along with spinal or para-peritoneal trauma, may convert the autonomic rules of colonic operation, taking to unreasonable parasympathetic repression or sympathetic excitement. This disparity results in colonic atony and distension. Prior acknowledgment and suitable maintenance are crucial to limiting unwholesome and death. The mortality rate is projected at 40% when ischemia or puncture appears. The best-studied therapy of sharp colonic pseudo-obstruction is hypodermic neostigmine, which takes prompt colon decompression in the abundance of patients after a single infusion.

  • Side Effects Related to the Medications

  • Lack of Knowledge in People

Intestinal Pseudo-obstruction Treatment Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Period

2026-2035

CAGR

5.1%

Base Year Market Size (2025)

USD 24.77 billion

Forecast Year Market Size (2035)

USD 40.73 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Intestinal Pseudo-obstruction Treatment Market Segmentation:

Drug Class Segment Analysis

The antibiotic segment in the intestinal pseudo-obstruction treatment market will grow the most by the forecast period and will hold almost 68% because of its extensive use in people across the world to treat intestinal pseudo-obstruction. Doctors cure chronic intestinal pseudo-obstruction with nutrition help, medicines, ease, and sometimes surgery. If a fundamental health issue is causing chronic intestinal pseudo-obstruction, doctors will also cure the basic health issue as required. According to the original description, Ogilvie attributed the large bowel colic to a violation of the sympathetic supply because of retroperitoneal spitefulness leaving the parasympathetic innervation unopposed. The shortage of inhibitory inputs would produce a neuropathophysiological instability leading to fitful colonic contraction causing a hindrance. The proximal bowel would then become heavily dilated under the impact of parasympathetic nerve trails.

Diagnosis Segment Analysis

The blood test segment in the intestinal pseudo-obstruction treatment market is expected to hold 38% of the revenue share owing to the increasing blood tests to detect the disease of intestinal pseudo-obstruction. Intestinal pseudo-obstruction is an unusual situation that can be tough to diagnose because your symptoms can mimic other maladies. With a team of gastrointestinal motility specialists and a devoted Neurogastroenterology, Motility, and Functional Disorders Program, they surpass in promptly and precisely diagnosing your situation at Stanford Health Care. Once they comprehend the source of your discomfort, they provide customized treatments so you can begin to feel better. A substitute hypothesis acknowledges the potential that tonic hyperactivity of exterior or interior inhibitory neurones may play a crucial role in the pathophysiology of Ogilvie’s syndrome.

Our in-depth analysis of the global intestinal pseudo-obstruction treatment market includes the following segments:

     Type
  • Acute
  • Chronic

     Treatment
  • Medication
  • Surgery
  • Diet
  • Decompression

     Diagnosis
  • Physical Exam
  • Biopsy
  • Blood Test
  • Gastric Emptying Tests
  • Imaging Tests, Manometry

     Symptoms
  • Abdominal Pain
  • Bloating
  • Diarrhea
  • Vomiting
  • Nausea
  • Constipation

     Dosage
  • Tablet
  • Injection

     Route of Administration
  • Oral
  • Intravenous

     End-User
  • Clinic
  • Hospital

     Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

     Drug Class
  • Antibiotic
  • Antidepressants
  • Antidiarrheal
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Intestinal Pseudo-obstruction Treatment Market Regional Analysis:

North America Market Insights

The intestinal pseudo-obstruction treatment market in the North America industry is anticipated to account for largest revenue share of 45% by 2035. This growth will be noticed owing to the increasing advancement in the tools of diagnosis in this region. An American Medical Association investigation demonstrated that 57% of physicians utilize or plan to utilize digital clinical support equipment in their work. The clinical determination support resource UpToDate is utilized in more than 190 countries and by 90% of US academic medical centers. Unifying this equipment into practice, specifically in sub-Saharan Africa, is a significant element of modifying the complete quality of healthcare. However, substantial gaps exist in the utilization of these gadgets in healthcare providers' routine exercises in low-resource settings.

Europe Market Insights

The intestinal pseudo-obstruction treatment market in the Europe region will also encounter huge growth during the forecast period and will hold the second position owing to the chronic digestive disease in this region. The chronic disease management is mostly common in European countries. More than 332 million people are anticipated to be living with a digestive disorder in the European region, in line with a report from the United European Gastroenterology (UEG). In an assessment of the epidemiology of digestive situations around 44 UEG member countries, the report recommends that, between 2000 and 2019, the age-standardized prevalence of digestive diseases enhanced only slightly, but as an outcome of modified survival, age-standardized frequency enhanced by 5%. Chronic liver disorders, pancreatitis, and gastro-oesophageal reflux disease (GORD) were among the digestive situations for which age-standardized incidence or age-standardized frequency had enhanced since 2000.

Intestinal Pseudo-obstruction Treatment Market size
Get Strategic Analysis by Region Now: Request Free Sample PDF

Intestinal Pseudo-obstruction Treatment Market Players:

    • GlaxoSmithKline Plc.
      • Company Overview
      • Business Planning
      • Main Product Offerings
      • Financial Execution
      • Main Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Abbott Laboratories
    • Pfizer Inc.
    • Johnson & Johnson
    • Callisto Pharmaceuticals Inc.
    • Biogen Inc.
    • Novartis A.G
    • Canila Healthcare Ltd
    • AbbVie Inc.
    • Eli Lilly and Company

Recent Developments

GSK Plc. declared that it has fulfilled the acquirement of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical organization concentrated on tackling the unmet treatment requirements of patients with respiratory and inflammatory situations.

GSK Plc. declared that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved for review the regulatory application of Shingrix for the prohibition of shingles (herpes zoster) in adults aged 18 years and more than at growing risk.

 

  • Report ID: 5760
  • Published Date: Sep 16, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of intestinal pseudo-obstruction treatment is estimated at USD 25.91 billion.

The global intestinal pseudo-obstruction treatment market size was more than USD 24.77 billion in 2025 and is anticipated to witness a CAGR of around 5.1%, crossing USD 40.73 billion revenue by 2035.

North America intestinal pseudo-obstruction treatment market is expected to capture 45% share by 2035, driven by increasing advancement in the tools of diagnosis in this region.

Key players in the market include GlaxoSmithKline Plc., Abbott Laboratories, Pfizer Inc., Johnson & Johnson, Callisto Pharmaceuticals Inc., Biogen Inc., Novartis A.G., Canila Healthcare Ltd, AbbVie Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited., Daiichi Sankyo Co Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co Ltd.

Intestinal Pseudo-obstruction Treatment Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos